STOCK TITAN

Acadia Pharmaceuticals Inc - ACAD STOCK NEWS

Welcome to our dedicated news page for Acadia Pharmaceuticals (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acadia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acadia Pharmaceuticals's position in the market.

Rhea-AI Summary
ACAD - Acadia Pharmaceuticals Inc. Reports Strong 2Q23 Financial Results with Net Product Sales of $165.2 Million, Expanded Licensing Agreement, and Positive Late-Stage Portfolio Progress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
Rhea-AI Summary
Acadia Pharmaceuticals Inc. has appointed Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer. Dr. Oliver will oversee all business development functions and will serve as a member of the company’s Executive Management Committee. His appointment comes at a pivotal time as Acadia aims to grow its portfolio of central nervous system assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
-
Rhea-AI Summary
Acadia Pharmaceuticals has expanded its licensing agreement with Neuren Pharmaceuticals to acquire ex-North American rights to trofinetide and global rights in Rett syndrome and Fragile X syndrome. This agreement solidifies Acadia's position as a global leader in addressing the unmet needs of people with Rett syndrome. Acadia also gains exclusive worldwide rights to Neuren's development candidate NNZ-2591. Financial terms include an upfront payment of $100 million to Neuren, as well as potential milestone and royalty payments. Preliminary net sales for the second quarter are $21 to $23 million for DAYBUE and $140 to $144 million for NUPLAZID.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
Acadia Pharmaceuticals Inc

Nasdaq:ACAD

ACAD Rankings

ACAD Stock Data

2.81B
109.87M
0.49%
99.56%
6.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ACAD

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies